Albuterol sulfate is a medication used primarily to treat bronchospasm for patients with obstructive airway disease such as asthma. It is approved for patients 2 years of age and older, according to the National Institute of Health 2. Albuterol sulfate comes in several forms: aerosol, solution for nebulizer, syrup, and tablets, according to "Lippincott’s Nursing Drug Guide". Albuterol is most commonly recognized by people when it is used as an asthma rescue medication in its inhaler form.
Clinical trials indicate patients who receive inhaled albuterol sulfate to treat bronchospasm have improved respiratory function within 5 minutes (SeeReferences2). Albuterol sulfate is also used to prevent exercise induced bronchospasm; inhalation form of the medication is taken 15 minutes before exercise (SeeReferences1).
Oral albuterol sulfate has a 30 minute onset, whereas inhaled albuterol sulfate has a 5 minute onset (SeeReferences1). This is why inhaled albuterol sulfate is used during acute episodes of bronchospasm.
An unlabeled use of albuterol sulfate is in treating hyperkalemia in dialysis patients (SeeRefernces1). The exact mechanism of action is unclear however extracellular shunting of potassium is suspected (SeeReferences2).
Drug class and Therapeutic Actions
Albuterol sulfate is a beta2-selective adrenergic agonist with sympathomimetic effects. Beta2 adrenergic receptors are nerve synapses that when stimulated release epinephrine. Adrenergic agonist medications stimulate these particular receptors, which are primarily found in bronchial (lung) smooth muscle. Another effect of beta2 adrenergic agonists is on the enzyme that converts adenosine triphosphate (ATP) to adenosine monophosphate (AMP) (SeeReferences2). ATP and AMP play a role in the body’s inflammatory response. Beta adrenergic agonists like albuterol sulfate interfere with this response, decreasing the body’s ability to react to allergens. This is important in helping to decrease inflammation in the respiratory tract; inflammation often accompanies bronchospasm with obstructive airway disease.
The effects of albuterol sulfate are dependent on the dose. Low doses cause bronchodilation and vasodilation in muscle, whereas higher doses have greater sympathomimetic effects such as tachycardia (rapid heart rate). A sympathomimetic drug is one that stimulates the sympathetic nervous system. Stimulation of this system causes rapid heart rate, dilated pupils, sweating and increased respiratory rate--symptoms similar to those experienced during fight or flight reactions.
The sympathomimetic effects of albuterol sulfate are important because some patients experience significant cardiovascular symptoms such as tachycardia, elevated blood pressure, and irregular heart rhythms after taking the medication. Other adverse effects include anxiety, restlessness, tremors and weakness.
Albuterol sulfate should be taken as directed. Increasing dosages and frequency may lead to paradoxical bronchospasm which can be life threatening, according to the National Institute of Health 2. Serious cardiovascular side effects may also occur with excessive use. Some patients may experience cardiovascular effects under normal dosing regimens, particularly with first use of new inhalation canisters.
Asthma symptoms may not improve with use of albuterol sulfate. Patients should seek medical attention when more than prescribed doses of albuterol are needed, or when symptoms of bronchospasm and respiratory compromise persist following treatment.
Albuterol sulfate is also used to prevent exercise induced bronchospasm; inhalation form of the medication is taken 15 minutes before exercise (SeeReferences1). Clinical trials indicate patients who receive inhaled albuterol sulfate to treat bronchospasm have improved respiratory function within 5 minutes (SeeReferences2). Patients should seek medical attention when more than prescribed doses of albuterol are needed, or when symptoms of bronchospasm and respiratory compromise persist following treatment.
- Karch, A. M. (2008). 2008 Lippincott’s Nursing Drug Guide. New York: Lippincott Williams & Wilkins
- National Institute of Health
- asthma inhaler image by Jenny Thompson from Fotolia.com